Le Lézard
Classified in: Health, Covid-19 virus

Charles Huang Foundation Makes Record-Breaking US$40 Million Donation to His Alma Mater, Wuhan University


PASADENA, Calif., Nov. 30, 2021 /PRNewswire/ -- Charles Huang Foundation (CHF) donated US$40 million to Wuhan University of China on Monday, November 29th at the celebration ceremony of the university's 128th anniversary, to express the Foundation founder and Chairman Charles Huang's appreciation to his alma mater and to promote the development of advanced education, health research and growth-driven innovation. This philanthropic gift is the single-largest personal donation ever received by Wuhan University. Together with the US$70 million landmark grant given by CHF to the University of Strathclyde in the UK in September, Dr Huang has donated a total of US$110 million to his two alma maters through his philanthropic foundation this year.

The donation was formally made at a virtual signing ceremony held between Wuhan University campus in China and the Foundation headquarters in Pasadena, California, earlier today.

The US$40 million funding will be used to support 6 programs named after Innova Medical Group Inc and Pasaca Capital Inc. These programs are aimed to provide significant and long-lasting support for Wuhan University to attract and recruit top scholars, develop and create innovative and entrepreneurial talents with exceptional leadership skills, and advance research and teaching capabilities, especially in the field of Management Science at Wuhan University's School of Economics and Management.

Dr. Huang, Founder and Chairman of CHF said, "My study in Wuhan University signified the starting point of my journey to the world beyond and I deeply believe that all my achievements are based upon the excellent education that I received."

"Today I'm fulfilling the promise I made to donate at least $100 million of my personal wealth to my alma maters in China and the UK upon my firm achieving tremendous business goals within 5 years after its formation," added Dr. Huang. 

Dr. Huang established the private equity firm, Pasaca Capital Inc., in Los Angeles at the end of 2016. Since then, Pasaca has delivered on Dr. Huang's vision to set the world record for rapid growth on revenue, speed and scale within the first 5 years. Pasaca has now earned its place among other legendary businesses globally.

"As his alma mater, we are very proud that Wuhan University helped to cultivate such a global visionary entrepreneur like Dr Huang. We would like to express our sincere thanks to our alumnus Dr Huang and the Charles Huang Foundation for this tremendously generous donation to the university, which will help us cultivate first-class innovative talents, enhance our capabilities in scientific research and innovation, and contribute to Wuhan University's development into a world-class university with uniquely Chinese characteristics," said Professor Dou Xiankang, President of Wuhan University.

About Charles Huang Foundation's Donation to Wuhan University

The US$40 million donation will mainly support six programs:

About Charles Huang PhD

Charles Huang, PhD is a Chinese American entrepreneur. Following the completion of his bachelor's degree in economics at Wuhan University, and MBA and PhD studies in the UK, Dr Huang joined James Capel (Now HSBC Securities) in Hong Kong where he became a pioneer in Chinese equity research. Later joining Crédit Lyonnais and BNP Paribas he was recognized as having "the Midas touch" because of his unrivaled stock selection skills and impeccable stock market calls. Dr Huang participated in and led over IPOs prior to becoming a celebrated business executive in private and publicly traded companies.

In 2016, Dr Huang founded Pasaca Capital Inc. in Pasadena, California with a focus on medical devices, pharmaceuticals, TMT, industrial & automation, and food ingredient sectors. One of Pasaca Capital's portfolio companies, Innova Medical Group Inc. is the global leader and the largest supplier of COVID-19 antigen rapid testing in the world.

Dr Huang was recently named "2021 Philanthropreneur of the Year" by the California State Assembly in recognition of the exceptional leadership. Pasaca Capital was also named "2021 Business of the Year" by the California State Assembly for its extraordinary contributions to the State of California and the world.

About Charles Huang Foundation

Charles Huang Foundation is a nonprofit public benefit corporation with a mission to accelerate and encourage education, health-related research, and entrepreneurship on a global platform. The Foundation works in partnership with governments, foundations, corporations, and institutions to establish educational and business opportunities that maximize the potential of aspiring scholars, researchers, and entrepreneurs.

 

SOURCE Charles Huang Foundation


These press releases may also interest you

at 04:00
Based in Augusta, Georgia, USA, Jinfiniti Precision Medicine is dedicated to increasing human health and lifespan by providing a range of rapid screening services to biomedical research institutions, nutraceutical companies, the longevity industry,...

at 04:00
The Celiac Disease Foundation, the nation's leading patient advocacy organization for celiac disease, announces its newest appointee, Casey Guber, to its Board of Directors. The officers for 2022 are Chair Adrienne Bender, Vice Chair John Wagner,...

at 03:46
Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the...

at 03:41
Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on AQSE Growth Market, is pleased to announce the appointment of Dr. Herbert Fritsche to the Board of...

at 03:01
Nova Mentis Life Science Corp. ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company...

at 03:00
SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has appointed Professor Michael J. Econs, MD as Clinical Advisor. Distinguished Professor of Medicine and Medical and Molecular Genetics at...



News published on 30 november 2021 at 22:59 and distributed by: